Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature
The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is expressed on the surface of developing B cells, but not the early progenitors or mature plasma cells. In 1997, ri...
Main Authors: | Luis Miguel Juárez-Salcedo, Diego Conde-Royo, Keina Quiroz-Cervantes, Samir Dalia |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2020-05-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://drugsincontext.com/use-of-anti-cd20-therapy-in-follicular-and-marginal-zone-lymphoma:-a-review-of-the-literature |
Similar Items
-
Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
by: Subramanian J, et al.
Published: (2017-04-01) -
Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges
by: Tayse Silva dos Santos, et al. -
Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review
by: Andrei Suponin, et al.
Published: (2024-02-01) -
Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment
by: Letizia Polito, et al.
Published: (2013-10-01) -
Influência do CD 20 na refratariedade do linfoma de Hodgkin clássico ao tratamento inicial com o esquema ABVD, no Ceará, Brasil Influence of CD 20 antigen expression in the refractoriness of classical Hodgkin lymphoma in the first line treatment with ABVD protocol in Ceará state, Brazil
by: Rogério Pinto Giesta, et al.
Published: (2009-06-01)